Prescription ·Strong evidence ·Reviewed May 2026
A third-generation cephalosporin with broad-spectrum activity against many gram-negative and gram-positive organisms. Administered parenterally (IM or IV), it is a cornerstone agent for community-acquired pneumonia, bacterial meningitis, gonorrhea, acute bacterial otitis media (when oral therapy fails), pelvic inflammatory disease, intra-abdominal infections, and complicated urinary tract infections. Its long half-life allows once-daily dosing.
The bottom line
Evidence rating strong. Most-documented uses: treats community-acquired pneumonia, treats bacterial meningitis, treats gonorrhea (recommended im regimen). 10 sources indexed (2012–2026), with 3 interaction records on file.
Core mechanism
Binds to penicillin-binding proteins (PBPs), disrupting the transpeptidation step of peptidoglycan cell wall synthesis. Third-generation cephalosporins are highly resistant to many beta-lactamases and have enhanced penetration through gram-negative outer membrane porin channels, resulting in potent gram-negative activity including against N. meningitidis, H. influenzae, and many Enterobacteriaceae. Achieves therapeutic CSF concentrations when meninges are inflamed.
Administered parenterally (IV or IM). 100% bioavailable by IM route. Not available in oral formulation. Widely distributed including to CSF when meninges are inflamed.
Nutrients this medication can lower over time, and what to replace.
Broad-spectrum antibiotic exposure can suppress gut bacteria that synthesize menaquinones, lowering vitamin K availability in susceptible patients.
Probiotic supplementation during ceftriaxone therapy reduces antibiotic-associated diarrhea and helps preserve gut microbiome diversity. This is particularly relevant because IV ceftriaxone is excreted in bile and disrupts colonic flora significantly.
Recommendation: Take probiotics throughout your ceftriaxone course. Continue for at least 1 week after the antibiotic ends.
Ceftriaxone suppresses vitamin K-producing gut bacteria and has been associated with hypoprothrombinemia and bleeding, particularly in malnourished patients, the elderly, or those with prolonged therapy. Although ceftriaxone lacks the N-methylthiotetrazole side chain seen in some bleeding-prone cephalosporins, gut flora suppression alone can lower vitamin K2 stores.
Recommendation: For short courses in well-nourished adults, no special action is needed. For prolonged therapy, malnutrition, elderly patients, or critical illness, monitor coagulation and discuss vitamin K2 supplementation with your clinician.
Ceftriaxone and calcium-containing IV fluids can form insoluble ceftriaxone-calcium precipitates in lung and kidney tissue, with fatal cases reported in neonates. The FDA contraindicates concurrent IV ceftriaxone and IV calcium-containing solutions in neonates under 28 days. In older patients and oral calcium supplementation, the risk is much lower, but the principle of avoidance still applies for IV co-administration.
Recommendation: Do not infuse IV ceftriaxone with calcium-containing IV solutions, especially in neonates. Oral calcium supplements are generally acceptable but should ideally be spaced from IV ceftriaxone doses. Discuss any IV co-administration with your clinical team.
Numbered references. Citations throughout the page link here.
Maraolo AE, Nobile M, Gentile I. Ceftriaxone for methicillin-susceptible Staphylococcus aureus bloodstream infections is associated with increased short-term mortality: a systematic review and meta-analysis. Annals of medicine. 2026
Comce MH, Weersink RA, Beuers U et al.. Pharmacokinetics of ceftriaxone, gentamicin, meropenem and vancomycin in liver cirrhosis: a systematic review. The Journal of antimicrobial chemotherapy. 2024
Zeng L, Wang C, Jiang M et al.. Safety of ceftriaxone in paediatrics: a systematic review. Archives of disease in childhood. 2020
Donnelly PC, Sutich RM, Easton R et al.. Ceftriaxone-Associated Biliary and Cardiopulmonary Adverse Events in Neonates: A Systematic Review of the Literature. Paediatric drugs. 2017
Zeng L, Choonara I, Zhang L et al.. Safety of ceftriaxone in paediatrics: a systematic review protocol. BMJ open. 2017
Bai ZG, Bao XJ, Cheng WD et al.. Efficacy and safety of ceftriaxone for uncomplicated gonorrhoea: a meta-analysis of randomized controlled trials. International journal of STD & AIDS. 2012
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack